Ironwood Pharmaceuticals is trading 5.21% up now at $4.34, primarily alongside biotech-sector gains in a broadly stronger market; no clear company-specific catalyst has been identified for August 25, 2026.
- Its latest notable company news was its August 6 second-quarter update.
- The update raised 2026 revenue guidance to $460–$485 million, but was not new today.